Encoded Therapeutics, Inc., a South San Francisco, Calif.-primarily based totally precision gene remedy employer, raised $104m in Series C financing.

Backers blanketed present shareholders Venrock, ARCH Venture Partners, Matrix Capital Management, Illumina Ventures, and Altitude Life Science Ventures and new traders Menlo Ventures, RTW Investments, Boxer Capital of Tavistock Group, and Alexandria Venture Investments.

The employer intends to apply the price range to strengthen its lead application in Dravet Syndrome and its preclinical pipeline, in addition to to leverage its platform to broaden new therapeutics to deal with excessive genetic issues.

Led through co-founder and leader govt officer Kartik Ramamoorthi, Ph.D., incubated through Illumina Accelerator and seeded through Venrock and ARCH Venture Partners, Encoded leverages a precision gene remedy platform, which has the cappotential to allow the improvement of gene remedies with cell-kind selectivity, potency, and the capacity to modulate the expression of endogenous genes.

The employer is centered on 4 center regions of research: neurocircuitry issues, liver and metabolic disease, neurodegeneration and cardiovascular disease. Initial applications use clinically-established adeno-related viral vectors (AAV), and provide the cappotential to cope with issues out of doors the attain of contemporary gene remedy era or drastically enhance the blessings of gene remedy in set up targets.

Encoded’s lead application is in Dravet syndrome, a excessive genetic ailment that happens in about 1 in 16,000 births worldwide. The ailment is characterised through out of control seizures, ataxia, sizeable developmental delays and an expanded danger of early mortality because of unexpected sudden dying in epilepsy (SUDEP).

The board participants include:

– Sean P. Nolan, Chairman, Former CEO at AveXis Inc.

– Kartik Ramamoorthi, Ph.D., Chief Executive Officer and co-founder

– Stephanie Tagliatela, Chief Scientific Officer and co-founder

– Bryan Roberts, Ph.D., companion at Venrock

– Robert Nelsen, coping with director at ARCH Venture Partners

– Karan Takhar, coping with director at Matrix Capital Management

– John R. Stuelpnagel, MBA, D.V.M., co-founding father of Illumina, Inc., chairman of 10x Genomics and Inscripta, Inc.